Your browser doesn't support javascript.
loading
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
Barry, Nathaniel; Francis, Roslyn J; Ebert, Martin A; Koh, Eng-Siew; Rowshanfarzad, Pejman; Hassan, Ghulam Mubashar; Kendrick, Jake; Gan, Hui K; Lee, Sze T; Lau, Eddie; Moffat, Bradford A; Fitt, Greg; Moore, Alisha; Thomas, Paul; Pattison, David A; Akhurst, Tim; Alipour, Ramin; Thomas, Elizabeth L; Hsiao, Edward; Schembri, Geoffrey P; Lin, Peter; Ly, Tam; Yap, June; Kirkwood, Ian; Vallat, Wilson; Khan, Shahroz; Krishna, Dayanethee; Ngai, Stanley; Yu, Chris; Beuzeville, Scott; Yeow, Tow C; Bailey, Dale; Cook, Olivia; Whitehead, Angela; Dykyj, Rachael; Rossi, Alana; Grose, Andrew; Scott, Andrew M.
Afiliación
  • Barry N; School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia. Nathaniel.barry@research.uwa.edu.au.
  • Francis RJ; Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia. Nathaniel.barry@research.uwa.edu.au.
  • Ebert MA; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Koh ES; Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, WA, Australia.
  • Rowshanfarzad P; School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
  • Hassan GM; Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia.
  • Kendrick J; Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, WA, Australia.
  • Gan HK; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Lee ST; Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centres, Liverpool, NSW, Australia.
  • Lau E; South Western Sydney Clinical School, UNSW Medicine, University of New South Wales, Liverpool, NSW, Australia.
  • Moffat BA; School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
  • Fitt G; Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia.
  • Moore A; School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
  • Thomas P; School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
  • Pattison DA; Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia.
  • Akhurst T; Department of Medical Oncology, Austin Hospital, Melbourne, VIC, Australia.
  • Alipour R; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
  • Thomas EL; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
  • Hsiao E; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
  • Schembri GP; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
  • Lin P; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
  • Ly T; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
  • Yap J; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.
  • Kirkwood I; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.
  • Vallat W; Department of Radiology, Austin Health, Melbourne, VIC, Australia.
  • Khan S; Department of Radiology, University of Melbourne, Melbourne, VIC, Australia.
  • Krishna D; Department of Radiology, University of Melbourne, Melbourne, VIC, Australia.
  • Ngai S; Department of Radiology, Austin Health, Melbourne, VIC, Australia.
  • Yu C; Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.
  • Beuzeville S; Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
  • Yeow TC; Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia.
  • Bailey D; Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
  • Cook O; Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia.
  • Whitehead A; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
  • Dykyj R; The Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia.
  • Rossi A; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
  • Grose A; The Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia.
  • Scott AM; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Eur J Nucl Med Mol Imaging ; 50(13): 3970-3981, 2023 11.
Article en En | MEDLINE | ID: mdl-37563351
ABSTRACT

PURPOSE:

The O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation.

METHODS:

Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBRmax), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR (TBRmax/TBRmean) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]).

RESULTS:

Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBRmax, and TBRmean were 21.53% (12.00-30.10%), 5.89% (5.01-6.68%), and 5.01% (3.37-6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63-0.97) with good spatial (DSC = 0.84 ± 0.09) and boundary (HD = 15.78 ± 8.30 mm; MASD = 1.47 ± 1.36 mm) agreement.

CONCLUSION:

The FIG study credentialing program has increased expertise across study sites. TBRmax and TBRmean were robust, with considerable variability in BTV delineation and image interpretation observed.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Ficus / Medicina Nuclear Tipo de estudio: Qualitative_research Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma / Ficus / Medicina Nuclear Tipo de estudio: Qualitative_research Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2023 Tipo del documento: Article País de afiliación: Australia